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Twenty-four children aged 12-17 years entered a randomized, double-blind placebo-controlled study 
investigating the use of salmeterol in chronic severe asthma. In addition to their usual medication, the children 
were given either placebo or 100,~g salmeterol b.d. by dry powder inhalation. Treatment was continued 
throughout one term at a residential school for asthma. Symptom scores, peak expiratory flow rates, 
spirometry and quality-of-life scores were compared between the two treatment groups. 
One child withdrew during the run-in period. Twelve pupils received placebo and 11 pupils received 
salmeterol. There were consistent improvements in favour of salmeterol, reaching statistical significance for 
morning and evening peak flow rates and spirometry when measured on four occasions during the study 
period. There were no medication-related adverse events recorded and no pulse rate changes. Salmeterol 
(100,~g b.d.) is well tolerated and efficacious in older children with chronic severe asthma. 
Introduction 
Due to their rapid onset of action, short-acting 
inhaled &agonists are recommended for use as relief 
therapy in symptomatic asthmatic children (l-6). 
Recently devised guidelines (7,8) recommend the 
early use of regular preventative therapies to control 
symptoms adequately, and reduce the possible risks 
which have been suggested when short-acting bron- 
chodilators are given in high doses on a regular basis 
(9-12). Despite the increasing use of preventative 
therapy over recent years, the morbidity from child- 
hood asthma remains high, with exercise-induced and 
nocturnal symptoms affecting the lifestyles of many 
patients (13). Although short-acting &agonists give 
rapid relief, their length of action prevents them from 
protecting patients for longer periods of time. The 
development of long-acting &agonists has been 
specifically aimed at addressing this problem. 
In adult patients, salmeterol given twice daily by in- 
halation has been shown to be effective for up to 12 h 
(14-16). In patients with mild to moderate asthma, a 
dose of 50,~g salmeterol b.d. improves morning and 
evening peak flows and reduces diurnal peak ilow 
variation (4,14,17). It is also effective in improving the 
quality of sleep in nocturnal asthma (18). 
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In children, salmeterol has been shown to produce 
effective bronchodilatation for up to 12 h (19), to 
protect against exercise-induced bronchoconstriction 
for up to 9 h (20) and to protect against 
methacholine-induced challenge for up to 12 h (21). 
A recent study in adult asthmatics found that in 
severe disease, 100 pug salmeterol b.d. was more effec- 
tive and equally well tolerated as 50,~g b.d. (22). No 
such study has been undertaken in children with 
severe asthma. The aim of this pilot study, therefore, 
was to evaluate the efficacy and safety of 1OOpg 
salmeterol b.d. in a group of children considered to 
have chronic severe asthma. 
Patients and Methods 
Twenty-four children aged 12-17 years were 
recruited. They were all residential pupils at Pilgrim’s 
School in Seaford, East Sussex, the National School 
for Asthma and Eczema. All had been referred to the 
school for their continuing education because their 
asthma had severely interfered with their local edu- 
cation causing them to miss a great deal of schooling. 
All had persistent asthma symptoms despite high 
dose corticosteroids. None had been treated previ- 
ously with long-acting &agonists. The 24 children 
had been at Pilgrim’s School for between 4 months 
and 4.5 yr. There were 7 girls and 17 boys. Their 
asthma had been diagnosed for 2-17 yr and there was 
a family history of asthma or atopy in 12 (50%). The 
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study took place over the school term January- 
March 1993. There was a 2-week run-in period 
followed by S-weeks treatment and then 2-weeks 
follow-up. Approval for the study had been granted 
by the local Ethics Committee. 
A parallel group design was chosen for this study 
because it was felt to be advantageous to perform the 
study in one school term to improve compliance and 
to complete the study in as many as possible of the 
children randomized. The number of subjects partici- 
pating in the study was limited to the number of 
pupils in the school with severe asthma who were not 
already receiving long-acting &agonists. This is 
probably a larger number of this particular group of 
adolescents than could readily be found in any other 
single centre. 
Informed parental and personal consent was 
gained before the start of the study. A full examina- 
tion was performed on all pupils. Demographic data 
were obtained, including clinical history of asthma, 
evidence of personal or family atopy and therapy 
details prior to the study. 
After the run-in period, the pupils received either 
1OOpg salmeterol b.d. or two placebo blisters b.d., 
both medications via the diskhaler in addition to 
their usual therapy. The study medications were 
allocated in a pre-determined random sequence in a 
double-blind manner. During the follow-up period, 
all pupils continued their usual therapy but did not 
continue with the study medication. Daily record 
cards were kept by all pupils throughout the study. 
They recorded the best of three peak expiratory flow 
rates (PEF) each morning and each evening together 
with day and night time symptom scores, both on 
a O-3 scale. They recorded day and night-time 
&-agonist use on a wall chart in the school sick bay, 
where the medications for all the pupils were kept. 
All the children performed lung function tests 
using a mini-Wright peak flow meter and a Micro 
Medical portable printer spirometer in the morning 
and evening on four separate occasions carefully 
supervised by SLH and JH. These were always 
performed first thing in the morning and last thing at 
night, before taking morning and evening medi- 
cation. The best of three manoeuvres was recorded 
for PEF and FEV,. These measurements were made 
in week 3 (at the end of run-in), in week 6 (the week 
before the midterm break), in week 11 (the last week 
of treatment) and in week 13 (the last week of the 
follow-up period). 
In addition to the concurrent reporting of symp- 
toms and PEF in daily record booklets, pupils com- 
pleted the Childhood Asthma Questionnaire Form C 
(CAQC). The CAQC requires individuals to report 
Table I Demographic details of salmeterol and placebo 
groups at the time of randomization 
Placebo Salmeterol 
(n= 12) (n=ll) 
Median age (years) (range) 14 (12-16) 15 (12-17) 
No. of girls 2 5 
No. of boys 10 
Height (cm) (SD) 152 (11) 15: (9) 
Personal history of atopy (%) 100 100 
Atopy in 1st degree relative (%) 33 73 
Median duration of asthma (yrs) 13 12 
No. on oral corticosteroids 2 2 
No. on inhaled corticosteroids 11 11 
No. on methylxanthines 1 2 
No. on anti-cholinergics 0 1 
the frequency of their symptoms together with their 
feelings about these and other quality-of-life related 
issues during the preceding 2 weeks. This use of 
self-report questionnaires, to obtain information 
about children’s perceptions of their symptom con- 
trol, is in keeping with views expressed previously in 
Archives of Diseases in Childhood advocating ‘com- 
prehensive approach to the assessment and treatment 
of childhood asthma’ (23). Quality-of-life question- 
naires provide an important indirect objective 
method of assessing asthma care. 
Pupils completed the CAQC under supervision on 
four occasions - at the end of the run-in period, after 
3 and 8 weeks of treatment and at the end of the 
follow-up period. The CAQC produces 5 sub-scale 
scores, the three of relevance to this study being 
self-reported severity (the frequency of five symptoms 
of severity of asthma), distress (feelings about these 
symptoms) and active quality of living (frequency 
and enjoyment of activities including swimming, 
sports and outdoor play). The reliability and con- 
struct validity of these scores have been reported 
(24,25). 
During weeks 3, 6, 11 and 13, the pupils and the 
investigators assessed the effectiveness of treatment 
according to a scale of ‘very effective’, ‘effective’, 
‘satisfactory’ or ‘ineffective’. Safety was assessed by 
asking pupils to report any adverse events (at least 
once a week to SLH and JH), particularly those 
relating to known side-effects of /$-agonists, includ- 
ing tremor and headache. Resting pulse rates follow- 
ing 10 min of quiet sitting were measured during 
weeks 3, 6, 11 and 13. 
The number of asthma exacerbations was recorded 
for each pupil. SLH and JH were present at the 
school on most days during the study and a clinical 
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Table 2 Summary of data collected from diary cards and rescue medication cards Figures based on aggregated data 
during the appropriate weeks of the study. First two rows are mean (SD) , other rows are median (range) 
Run-in 
week 2 
Placebo 
8 weeks 
treatment 
Follow-up Run-in 
week 2 week 2 
Salmeterol 
8 weeks 
treatment 
Follow-up 
week 2 
% predicted mean 90.1 (15.9) 91.0 (14.1) 89.6 (13.3) 91.9 (19.3) 96.3 (20.3) 94.8 (18.0) 
morning PEF 
(I min - ‘) 
% predicted mean 92.0 (13.8) 94.7 (12.8) 95.1 (12.7) 950 (16.9) 98.0 (19.0) 98.3 (158) 
evening PEF 
(1 min - ‘) 
% symptom-free 50.0 39.9 100 16.7 44.4 66-7 
days (O-100) (O-100) (OGlOO) (O-100) (9.3-100) (O-100) 
% of symptom-free 57.1 45.5 87.5 42.9 67.9 75.0 
nights (O-100) (11.8-100) (50-100) (O-100) (24.5-100) (O-100) 
diagnosis of an asthma exacerbation was made 
after seeing each pupil and scrutinizing the diary 
score card. Wherever possible, exacerbations were 
managed by the same physician (SLH). 
Statistics 
Analysis was performed on an ‘intention to treat’ 
basis on all randomized pupils. Demographic data 
and the changes in PEF, FEV, diary symptom score 
card data, use of short-acting &agonist rescue medi- 
cation, quality-of-life data and the number of adverse 
events and asthma exacerbations were tabulated. 
Where trends of changes from baseline values were 
seen, comparisons between the two groups were 
performed using t-tests. 
Week of study 
Run-in Treatment period Follow-up 
Fig. I Mean clinic visit values for FEV,. 0, % predicted 
morning FEV, salmeterol; 0, % predicted night FEV, 
salmeterol; 0, % predicted morning FEV, placebo; A; % 
predicted night FEV, placebo. 
Results (range 50-1OOOpg b.d.). The demographic details are 
shown in Table 1. 
One pupil withdrew during the run-in period Morning PEF, percentage of symptom-free days 
because he did not fulfil entry criteria of severe and nights and percentage of days where no rescue 
asthma and received no study medication. The medication was needed all showed trends towards 
remaining 23 pupils were studied and their results improvement in the salmeterol-treated group. A wide 
analysed on an ‘intention to treat’ basis. Eleven variation in the percentage of symptom-free days and 
pupils were randomized to receive salmeterol and 12 nights was seen in the placebo-treated group during 
to receive placebo. Two pupils withdrew during the the run-in, treatment and follow-up periods (Table 
study period, both from the placebo group, one pupil 2). Similar figures were found for the percentage of 
withdrew after 2 weeks of treatment because of days and nights in which no rescue medication 
failure to comply with the study requirements and (short-acting &agonists) was required. This may 
one pupil withdrew after 3 weeks because of failure to partially be a reflection of the haphazard way in 
attend appointments. which diary score cards are used by some adolescents. 
The groups were similar for age, sex, duration of A trend in favour of salmeterol was seen in the 
asthma symptoms, previous treatment and history of clinic visit lung function testing (Fig. 1). These 
atopy. All pupils were being treated with corticoster- changes in the morning and evening PEF and FEV, 
oids, the median inhaled dose being 400,ug b.d. at the end of treatment compared to baseline were 
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Table 3 Changes in clinic-measured FEV, at end of treatment compared with baseline values 
Placebo (n = 10) Salmeterol (M= 11) 95% CI P-value 
Change in morning 
PEF (1 min ‘) (SD) 
Change in evening 
PEF (1 min ‘) (SD) 
Change in morning 
FEV, (1 min - ‘) (SD) 
Change in evening 
FEV, (1 min - ‘) (SD) 
- 35 (63) +26 (49) 112.3-9.7 co.05 
- 42 (64) +48 (52) 143.0-37.0 co.05 
- 0.20 (0.16) +0.22 (0.32) 0.65-0.19 CO.05 
- 0.16 (0.30) +0.20 (0.33) 0 65-0.07 co.05 
statistically significant in favour of the salmeterol- 
treated children (Table 3). The physician’s and 
patients’ assessment of treatment efficacy were 
similar for both treatment groups. Most graded the 
treatment as ‘effective’ or ‘very effective’. 
Four pupils in the placebo-treated group experi- 
enced a total of 13 exacerbations, whilst in the 
salmeterol-treated group, six pupils experienced a 
total of 9 exacerbations. In the placebo-treated 
group, three children received four courses of oral 
corticosteroids for the management of exacerbations, 
with three children receiving three courses in the 
salmeterol-treated groups. These differences were not 
statistically significant. 
Changes in individuals’ perceptions of their 
asthma were investigated by comparing changes in 
scores on the CAQC between the end of baseline 
and after 8 weeks of treatment. There was support 
for the efficacy of salmeterol with the change in 
self-reported severity being significantly greater for 
the salmeterol group (score improved by 3.0 points) 
than for the placebo group (score deteriorated by 
0.89 points) (P=O.O18). Distress and quality-of- 
living scores did not change significantly during the 
&week trial, nor were there significant differences 
in these score changes between the two treatment 
groups. 
Of the 11 pupils receiving salmeterol, 10 (91%) 
reported adverse events during the treatment period, 
compared with nine (75%) of the pupils receiving 
placebo. The vast majority of reported events were 
due to minor viral respiratory infections. None were 
drug-related nor led to withdrawal of the study 
medication. One child (from the salmeterol-treated 
group) required hospitalization for an acute exacer- 
bation of asthma. There was a small and insignificant 
rise in mean pulse rates at the end of treatment 
compared to baseline values in both the placebo- 
treated group (93 from 87 beats min - ‘) and the 
salmeterol-treated group (91 from 79 beats min ~ I). 
Discussion 
This study was carried out in a group of children 
whose asthma had become difficult to manage in the 
home environment and whose symptoms were 
deemed sufficient to warrant offering them residential 
schooling. This was largely due to severity but may 
have been compounded by a number of factors 
including compliance with medical therapy and the 
complexity of the family dynamics. Attendance at 
Pilgrim’s School meant that there was more super- 
vision than would normally be attained in the general 
population and more ready access to lung function 
equipment. The opportunity for improved compli- 
ance and the ability to measure lung function objec- 
tively was considered to be advantageous for a study 
involving a higher dose of salmeterol than previously 
studied. This study was designed to determine 
whether the dose of lOOpug b.d. is both efficacious 
and safe in older children with severe asthma. 
The amount of useful information that could be 
retrieved from the diary cards was disappointing. The 
information about symptoms and use of rescue medi- 
cation showed a very wide range. Close monitoring 
and checking of the pupils during this study was 
possible. The authors observed some occasions when 
the diaries were not completed at the appropriate 
time. It is unlikely that these pupils would accurately 
remember day and night-time symptom scores and 
twice daily peak flow rates (even if they had been 
performed) although they did record their results. 
This occurred despite repeated instructions from the 
authors that it was preferable to leave a blank than 
guess the information. The information in Table 2 
becomes very difficult to interpret. It is unlikely that 
patients in the community using diary cards for 
several weeks at a time are any better at recording 
information correctly. Electronic diaries which 
record the timing of data entry and of peak flow rates 
as suggested by Hyland (26) may be the only way of 
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improving this information, and so allowing some 
meaningful interpretation to be performed. 
All parameters of clinic-measured lung function 
improved during the 8-week study period in the 
children treated with salmeterol, compared with a 
tendency to worsen in the group treated with pla- 
cebo. There were clear and significant differences in 
lung function at the end of the study period. The 
deterioration in lung function in the placebo-treated 
group was notable. This may be explained by the 
previously described pattern of seasonal variation in 
asthma symptoms (27729). 
Subjectively, neither the patients nor the physicians 
were able to discriminate between the two treatment 
groups in terms of efficacy. Despite our reservations 
about the quality of the recording in the diary score 
cards, there was a trend for improvement in both 
day and night-time symptom scores, the number of 
symptom-free days and nights and the quality of life 
in favour of salmeterol. 
Although changes were seen in the self-reported 
severity of symptoms between the two treatment 
groups, distress and active quality-of-living scores did 
not change. It is possible that whilst 8 weeks is long 
enough to detect changes in patients’ direct percep- 
tions of their symptoms, it may take longer to 
produce similar changes in the psychological and 
behavioural aspects of symptoms. 
No medicine-related adverse events were reported, 
and the incidence of pharmacologically predictable 
adverse events was low. In particular, pulse rates 
were not raised in the pupils taking 100 pg salmeterol 
b.d. 
This small study does indicate that 100,ug 
salmeterol b.d. is well tolerated in this group of older 
children with chronic severe asthma. Lung function 
shows some improvement compared with placebo 
and there are objective improvements in quality-of- 
living scores. 
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